Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Methodological issues and therapeutic perspectives in vascular dementia: areview
Autore:
Dib, M;
Indirizzi:
Hop La Pitie Salpetriere, Serv Neurol, Lab Aventis, Direct Med, F-75601 Paris 12, France Hop La Pitie Salpetriere Paris France 12 t Med, F-75601 Paris 12, France
Titolo Testata:
ARCHIVES OF GERONTOLOGY AND GERIATRICS
fascicolo: 1, volume: 33, anno: 2001,
pagine: 71 - 80
SICI:
0167-4943(200107/08)33:1<71:MIATPI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
MULTI-INFARCT DEMENTIA; ALZHEIMERS-DISEASE; DOUBLE-BLIND; APOLIPOPROTEIN-E; RISK-FACTORS; DIAGNOSTIC-CRITERIA; CLINICAL-CRITERIA; EPSILON-4 ALLELE; NINDS-AIREN; PROPENTOFYLLINE;
Keywords:
vascular dementia; clinical trials; diagnosis; nootropic drugs;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
62
Recensione:
Indirizzi per estratti:
Indirizzo: Dib, M Hop La Pitie Salpetriere, Serv Neurol, Lab Aventis, Direct Med, 46 Quai Rapee, F-75601 Paris 12, France Hop La Pitie Salpetriere 46 Quai RapeeParis France 12 12, France
Citazione:
M. Dib, "Methodological issues and therapeutic perspectives in vascular dementia: areview", ARCH GER G, 33(1), 2001, pp. 71-80

Abstract

Vascular dementia (VaD) is the most common form of dementia after Alzheimer's disease (AD). However, it is now increasingly recognized that not only is VaD a heterogeneous syndrome but also that VaD and AD are not mutually exclusive. Thus, the currently used criteria may no longer be sufficient foran accurate diagnosis of VaD. In addition, although it is widely assumed that risk factors for vascular disease are also risk factors for VaD, the evidence, in most cases, is circumstantial. For the effective prevention of VaD, therefore, large-scale and long-term clinical trials are required to investigate the validity of these putative risk factors. These trials should also include the VaD subtypes in their outcome measurements and to this enda simplified classification system should be adopted. Additional large-scale trials are required to facilitate the secondary prevention and symptomatic treatment of VaD, in particular to investigate the potential applicationof several nootropic and neuroprotective drugs. In both cases, these clinical trials should aim to move the field of VaD from opinion-based medicine to evidence-based medicine. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 15:23:09